digital currency country- Top Featured snippets

CEO of Bank of America: The sales and trading business is expected to reach a new high in the fourth quarter, and the investment banking business income will jump. On December 11th, the CEO of Bank of America Brian moynihan said that with the "continuous growth" of transactions, the bank's investment banking business income in the fourth quarter may exceed US$ 1.4 billion, with a year-on-year increase of at least 25%. Moynihan also said that the sales and trading business in the fourth quarter should record a year-on-year growth again, achieving a medium-to-high single-digit growth. The bank also expects that the net interest income will continue to grow, which is expected to achieve the guiding target of $14.3 billion given earlier this year.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)ING is bearish on the prospect of commodities next year. It is expected that gold will outshine others. ING said that energy and commodities will be under pressure next year, while the prospect of gold is still bright. According to ING, due to geopolitical concerns, the price of gold is bound to continue this year's record high, and the average price of gold in 2025 will rise from about $2,713 per ounce at present to $2,760 per ounce. Most of the buying will come from central banks seeking diversification of foreign exchange reserves, and the intensification of trade and geopolitical frictions may increase the safe-haven appeal of gold.

The Nikkei 225 index closed up 1.21% at 39,849.14.US media: "Ukraine provides drones to Syrian opposition forces." According to Reuters's December 11th quote from Washington post, a few weeks before Syrian opposition forces launched an offensive and overthrew former President Bashar al-Assad, Syrian militants obtained about 150 drones and other secret support from Ukrainian intelligence personnel. Washington post quoted unnamed sources familiar with Ukrainian military activities as saying that four to five weeks ago, Ukrainian intelligence agencies sent about 20 drone operators and about 150 drones to help the "Syrian Sham Liberation Army". According to the report, the Russian Foreign Ministry said earlier that the Syrian opposition armed forces obtained drones from Ukraine and received operational training. The Russian Foreign Ministry did not provide evidence. At that time, the Ukrainian Foreign Ministry said that it "categorically" denied this statement. (Reference message)In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for the replacement of generic drugs. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)

China Merchants Securities: Hisense's household appliances are obviously underestimated, and the safety cushion is thick, and it is rated as "strongly recommended". China Merchants Securities Research Report pointed out that the growth rate of Hisense's household appliances (000921.SZ) slowed down, showing the first year-on-year decline in nine quarters since 22Q3, and the market confidence was weak. The company is obviously underestimated, and the safety mat is thick. Looking horizontally, in 2025, the valuations of Hisense, Midea and Haier will be 10/13/13 times; Historically, the company's share price has been deeply adjusted since May this year, and the current valuation is at a lower level since the 22-year reform. Referring to the global valuation system, the steady-state PE hub of johnson controls/Carrier/Trane is 30/25/20 times, which is higher than the valuation of white power enterprises represented by Whirlpool and Electrolux. Hisense household appliances, as the standard of A-share central air conditioning, should enjoy a higher valuation than white power companies. The improvement of the company's bottom management promotes efficiency and cost reduction+the global operation competitiveness is constantly strengthened+the company's leading position is stable under the background of domestic substitution of central air conditioning, and it continues to be firmly optimistic about the company. It is estimated that the company's revenue will increase by +8%, +9% and +10% from 2024 to 2026, and its performance will increase by +15%, +14% and +16% respectively. Give a "strongly recommended" rating.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)Israeli: Community alarm sounded near Gaza.